Zhang Jing, Zhong Qing
Department of Internal Medicine, Center for Autophagy Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Room Y9206C, Dallas, TX, 75390-9113, USA.
Cell Mol Life Sci. 2014 Oct;71(20):3885-901. doi: 10.1007/s00018-014-1656-6. Epub 2014 Jun 5.
Histone deacetylases (HDACs) are a vast family of enzymes involved in chromatin remodeling and have crucial roles in numerous biological processes, largely through their repressive influence on transcription. In addition to modifying histones, HDACs also target many other non-histone protein substrates to regulate gene expression. Recently, HDACs have gained growing attention as HDAC-inhibiting compounds are being developed as promising cancer therapeutics. Histone deacetylase inhibitors (HDACi) have been shown to induce differentiation, cell cycle arrest, apoptosis, autophagy and necrosis in a variety of transformed cell lines. In this review, we mainly discuss how HDACi may elicit a therapeutic response to human cancers through different cell death pathways, in particular, apoptosis and autophagy.
组蛋白去乙酰化酶（HDACs）是一个参与染色质重塑的庞大酶家族，在众多生物学过程中发挥关键作用，主要是通过其对转录的抑制作用。除了修饰组蛋白外，HDACs还作用于许多其他非组蛋白蛋白质底物以调节基因表达。最近，随着HDAC抑制化合物作为有前景的癌症治疗药物被开发，HDACs受到越来越多的关注。组蛋白去乙酰化酶抑制剂（HDACi）已被证明能在多种转化细胞系中诱导分化、细胞周期停滞、凋亡、自噬和坏死。在本综述中，我们主要讨论HDACi如何通过不同的细胞死亡途径，特别是凋亡和自噬，引发对人类癌症的治疗反应。
